Abbott’s $21bn Exact Sciences Deal Underscores Medtech Valuations at Discount
EY’s latest medtech report shows industry volumes rising mid-to-high-single digits with stable pricing and dealmaking focused on fewer, higher-value transactions including Abbott’s $21bn Exact Sciences acquisition. Medtech valuations have compressed to a discount versus the S&P 500 due to investor preference for AI and geopolitical uncertainties, despite 2025 M&A strength.
1. Industry Growth and Pricing
Medtech volumes increased mid-to-high-single digits in 2025 with pricing largely stable, reflecting robust fundamentals across device segments despite geopolitical headwinds. Direct sales impact from Middle East tensions remains limited at approximately 2–3%, though inputs like semiconductors sourced from Asia pose potential cost risks.
2. Deal Activity Highlights
2025 dealmaking was judicious, featuring major transactions such as Abbott’s $21bn acquisition of Exact Sciences and Boston Scientific’s $14.5bn purchase of Penumbra. In early 2026, MiniMed raised $560m in its IPO and Medtronic completed the acquisition of Scientia Vascular, marking a modest pickup in M&A.
3. Valuation Compression and Outlook
Investor focus on AI-driven medtech has driven multiple compression, bringing high-growth company valuations closer to lower-growth peers and pushing the sector below its historic premium to the S&P 500. As AI integration expands and geopolitical concerns subside, valuations may realign toward median or premium levels given solid underlying fundamentals.